Tagged with

Dr. F. Köhler Chemie Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community. What have been the main challenges you faced when taking over the company 25 years ago and becoming its General…

LEEM - Les Enterprises du Medicament What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies which seek to develop, manufacture and market drugs. Leem represents all components of the profession: international groups, medium-sized companies, an important fabric of small,…

July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you explain to us why it took so long in France to implement such a measure, while in most developed markets…

FPS - Facophar Santé FPS is a hundred year old organization with roots in the beginning of the last century representing today SME suppliers to the health industries. Given the variety of its membership what are the current priorities of FPS and how does the organization stay relevant to its multiple industries? Firstly I…

US pharmaceutical companies have long been in the French market but in your experience how do you feel they have integrated the differences in culture? Is this a finished topic in this industry? In France, many US companies are in reality French companies, meaning most general managers are French, and…

GEMME Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap has been narrowed very quickly as highlighted by public opinion and the fact everyone knows about generic drugs, but how…

LEEM - Les Enterprises du Medicament Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up? I think France has kept up with the world market albeit with some notable differences, namely in terms of our…

The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative drugs? It’s simple to explain as the market place doesn’t work for drugs for quite serious reasons. Primarily, the end-user…

The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain to our readers the main differences between this organization in France and the US FDA? AFSSAPS was created in 1999…

  Boasting three Nobel Prize winners from the life sciences, Argentina has had a long history of innovation. Immigration from Europe at the end of the 19th century saw the genesis of many of the national pharmaceutical companies that today control over 53% of the market. Access to highly qualified…

France What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that we can no longer live during this crisis without letting people express themselves genuinely. And I don’t mean expression of…

Paion Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company we see today? The reason for founding Paion in 2000 was more a question of timing of our own development.…